NCT02921620
Withdrawn
Phase 3
A Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease Patients
Protalix0 sitesJuly 2017
ConditionsFabry Disease
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Fabry Disease
- Sponsor
- Protalix
- Primary Endpoint
- IBSSS Part 1
- Status
- Withdrawn
- Last Updated
- 8 years ago
Overview
Brief Summary
The study will be a randomized, double blind, placebo-controlled study of the safety and efficacy of PRX-102 in ERT naïve male patients randomized 1:1. Patient age will be 14 to 45 years. Patients must have diarrhea defined as ≥ 3 stools a day with an average consistency of ≥ 5.5 on the Bristol Stool Form Scale (BSFS) by patient electronic diary and moderate to severe gastrointestinal symptoms as defined by the Irritable Bowel Symptom Severity Score (IBSSS) Part 1 average > 175 derived from at least two IBSSS assessments during screening period. Patients will receive intravenous infusions of PRX-102 1 mg/kg or placebo every two weeks for 6 months.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Males, age 14-45 years, naïve to enzyme replacement therapy (ERT) or off ERT or off chaperone treatment for at least 6 months and negative for anti-PRX-102 antibodies
- •A documented diagnosis of Fabry disease: Plasma and/or leucocyte alpha galactosidase activity (by activity assay) less than lower limit of normal (LLN)
- •eGFR by CKD-EPI \> 30 ml/min/1.73 m2
- •Moderate to severe gastrointestinal symptoms as defined by:
- •Average score of \> 175 from at least two Irritable Bowel Symptom Severity Score (IBSSS) Part 1 assessments before randomization.
- •Average stool consistency of ≥ 5.5 on the Bristol Stool Form Scale (BSFS) by patient diary during 2 weeks prior to randomization out of the 4 week of screening period and
- •≥ 3 stools a day with a consistency of ≥ 5 on the BSFS during the week before randomization.
- •Completed electronic BSFS diary on at least 6 of the 7 days during the week prior to randomization AND at least 11 of the 14 days during the 2 weeks prior to randomization.
Exclusion Criteria
- •Patients will be evaluated to rule out other gastrointestinal comorbidity than Fabry disease as responsible for the gastrointestinal symptoms by:
- •i. Medical History for non Fabry gastrointestinal comorbidity ii. Occult blood in stool iii. Stool culture for bacteria and parasites iv. Calprotectin in stool v. Sigmoidoscopy
- •Use of any kind of laxatives
- •Initiation of anti-diarrheal medications during the screening period
- •History of renal dialysis or transplantation
- •Use of, or change in dose of, angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) for less than 4 weeks prior to screening
- •Cardiovascular event (myocardial infarction, unstable angina) in the 6 month period before randomization
- •Congestive heart failure NYHA Class IV
- •Cerebrovascular event (stroke, transient ischemic attack) in the 6 month period before randomization
- •Known history of hypersensitivity to Gadolinium contrast agent
Outcomes
Primary Outcomes
IBSSS Part 1
Time Frame: Every 2 weeks for 6 months
Irritable Bowel Syndrome Severity Score
Secondary Outcomes
- Plasma Lyso-Gb3(Every 4 weeks for 6 months)
- Plasma Gb3(Every 4 weeks for 6 months)
- Urine Lyso-GB3(Every 6 weeks for 6 months)
- Stool frequency(After every bowel movement for 6 months)
- Body Weight(Every 2 weeks for 6 months)
- Frequency of pain medication use(Every 2 weeks for 6 months)
Similar Trials
Completed
Phase 2
Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)NASH - Nonalcoholic SteatohepatitisNCT0492948389bio, Inc.222
Terminated
Phase 2
A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis LipoidicaNecrobiosis LipoidicaNCT04800562Processa Pharmaceuticals4
Completed
Phase 3
Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) PatientsPhenylketonuriaNCT01114737BioMarin Pharmaceutical206
Completed
Phase 2
Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract InfectionsComplicated Urinary Tract InfectionAcute PyelonephritisNCT03445195Entasis Therapeutics80
Completed
Phase 2
Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes MellitusType1 Diabetes MellitusNCT03117998REMD Biotherapeutics, Inc.154